Tech Company Financing Transactions

Edgewise Therapeutics Funding Round

Viking Global Investors, Cormorant Asset Management and CureDuchenne Ventures participated in a $95 million Series C funding round for Edgewise Therapeutics. The round closed on 12/10/2020.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series C
Proceeds Purpose
Proceeds from the financing will be used to advance clinical development of Edgewise's lead drug candidate, EDG-5506, for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD), as well as the company's other rare disease programs.

Company Information

Company Status
Mailing Address
3415 Colorado Ave.
Boulder, CO 80304
Email Address
Edgewise Therapeutics is a new company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury.
Edgewise Therapeutics LinkedIn Company Profile
Social Media
Edgewise Therapeutics Company Twitter Account
Company News
Edgewise Therapeutics News
Edgewise Therapeutics on Facebook
Edgewise Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Kevin Koch
  Kevin Koch LinkedIn Profile  Kevin Koch Twitter Account  Kevin Koch News  Kevin Koch on Facebook
Chief Financial Officer
Michael Carruthers
  Michael Carruthers LinkedIn Profile  Michael Carruthers Twitter Account  Michael Carruthers News  Michael Carruthers on Facebook
Chief Medical Officer
Kirsten Gruis
  Kirsten Gruis LinkedIn Profile  Kirsten Gruis Twitter Account  Kirsten Gruis News  Kirsten Gruis on Facebook
Chief Scientific Officer
Alan Russell
  Alan Russell LinkedIn Profile  Alan Russell Twitter Account  Alan Russell News  Alan Russell on Facebook
Vice President
Abby Bronson
  Abby Bronson LinkedIn Profile  Abby Bronson Twitter Account  Abby Bronson News  Abby Bronson on Facebook
VP - Bus. Development
Behrad Derakhshan
  Behrad Derakhshan LinkedIn Profile  Behrad Derakhshan Twitter Account  Behrad Derakhshan News  Behrad Derakhshan on Facebook
VP - General Counsel
John Moore
  John Moore LinkedIn Profile  John Moore Twitter Account  John Moore News  John Moore on Facebook
VP - Regulatory Affairs
Nicole Kilburn
  Nicole Kilburn LinkedIn Profile  Nicole Kilburn Twitter Account  Nicole Kilburn News  Nicole Kilburn on Facebook



Browse more venture capital transactions:

Prev: 12/10/2020: Squire Technologies venture capital transaction
Next: 12/10/2020: Arthur venture capital transaction


Share this article


About Our VC Transactions Data

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary